Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Biobot Analytics is raising $20,833,737.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mariana Matus played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Biobot Analytics
Biobot Analytics develops cutting-edge technology to transform sewers into public health observatories. Wastewater contains valuable information about the health of communities. We collect it. We analyze it. We tell you how to leverage it to make your city better. Our first product is to measure opioids and other drug metabolites in sewage to estimate consumption in cities. With this data, those working on harm reduction can assess the scope of the epidemic, allocate resources, and gauge the effectiveness of programming over time. Founded by a biologist and an architect, our team has exemplified the power of interdisciplinary collaboration from its beginning. Inspired by the potential of wastewater epidemiology, Biobot is the first company in the world to commercialize data from sewage. After winning multiple entrepreneurship competitions at MIT, including a place in the DeltaV and DesignX accelerators, Biobot completed the Y Combinator accelerator in San Francisco. Headquartered in the Boston area, we aim to extend our wastewater epidemiology platform across all five continents.

To learn more about Biobot Analytics, visit http://www.biobot.io/

Contact:
Mariana Matus, Chief Executive Officer
857-756-5927
mariana@biobot.io
https://www.linkedin.com/in/marianamatus/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved